Last updated: February 27, 2026
What is the drug registered under NDC 49483-0699?
NDC 49483-0699 pertains to Subcutaneous Ustekinumab (Stelara), a biologic therapy indicated for the treatment of conditions such as Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Ustekinumab is an anti-IL-12/23 monoclonal antibody developed by Johnson & Johnson.
What is the current market landscape?
Market Size
The global biologics market for autoimmune diseases was valued at approximately USD 123 billion in 2022. Ustekinumab holds a significant share within this segment, estimated at USD 4-6 billion annually.
Key factors influencing the market include:
- Increasing prevalence of autoimmune and inflammatory diseases.
- Rising adoption of biologic therapies for chronic conditions.
- Expanding licensed indications, including Crohn's disease and psoriasis.
- Competition from biosimilars and alternative biologics like adalimumab and infliximab.
Competitive Landscape
Major competitors include:
- Adalimumab (Humira) – Dominant in autoimmune biologics with global sales over USD 20 billion in 2022.
- Infliximab (Remicade) – Approximate USD 8 billion annual sales.
- Secukinumab (Cosentyx) – Approx. USD 4 billion.
- Biosimilars for Stelara in select markets are beginning to enter, influencing pricing dynamics.
Regulatory Trends
- Ustekinumab approved by FDA in 2009 for psoriasis.
- Expanded approvals for Crohn's disease and ulcerative colitis through 2016-2022.
- Biosimilar development and approval processes underway in Europe and the U.S., expected to influence pricing and market share from 2024 onward.
How is the drug priced globally?
U.S. Pricing
- Average Wholesale Price (AWP): Approximately USD 4,200 per 45 mg and 90 mg injection.
- Average Transaction Price: Estimated USD 3,200 - USD 3,600 per dose.
- Patient Out-of-Pocket Costs: Varies based on insurance; annual costs average USD 8,000-USD 14,000.
European Pricing
- Prices vary by country, generally 20-40% lower than U.S. prices.
- Reimbursement often negotiated via national health systems.
- Typical per-dose costs: EUR 2,700- EUR 4,500.
Biosimilar Impact
- Biosimilars entering the market could lower prices by 20-50% in Europe.
- The U.S. biosimilar landscape remains limited; prices tend to stay near originator levels due to limited competition.
What are the projections for price trends?
| Year |
U.S. Average Price (USD) |
European Average Price (EUR) |
Comments |
| 2023 |
3,600 |
2,700 |
Stable; biosimilar entry limited |
| 2024 |
3,500 |
2,600 |
Slight decrease as biosimilars launch in Europe |
| 2025 |
3,200 |
2,300 |
Biosimilar adoption accelerates, prices decline |
| 2026 |
3,000 |
2,000 |
Increased biosimilar competition in Europe and U.S. |
Drivers of Price Declines
- Biosimilar approval and market entry.
- Negotiation pressure from healthcare payers.
- Volume-based discounts.
- Policy shifts towards cost containment in healthcare systems.
Key Risks and Opportunities
-
Risks:
- Slow biosimilar adoption in the U.S.
- Patent litigations delaying biosimilar launches.
- Regulatory delays in new indications or formulations.
- Market saturation and stiff competition.
-
Opportunities:
- Expansion into new indications (e.g., hidradenitis suppurativa).
- Development of subcutaneous formulations with improved dosing schedules.
- Market penetration in emerging economies with lower pricing models.
Summary of the outlook
- The U.S. market will see modest price reductions through 2026, with prices stabilizing around USD 3,000-3,500 per dose.
- European prices are expected to decline more noticeably, aligning with biosimilar entry and policy reforms.
- Overall market volume growth driven by increased diagnosis and expanded indications will sustain revenues for the originator, despite pricing pressures.
Key Takeaways
- Ustekinumab (NDC 49483-0699) remains a high-value biologic within the autoimmune therapeutics space.
- Pricing will face downward pressure from biosimilars, especially in Europe.
- Market expansion into new indications and geographic regions presents growth opportunities.
- The overall revenue valuation of the drug will depend on biosimilar adoption rates and policy changes.
FAQs
1. When will biosimilars for Stelara be widely available in the U.S.?
Biosimilar candidates have received FDA approval, but market entry depends on patent litigation and manufacturer strategies. Full market penetration is estimated around 2025-2026.
2. How much can prices decline with biosimilar competition?
Prices may decrease by 20-50% in established markets, influenced by manufacturer pricing strategies and payer negotiations.
3. What are the primary indications driving demand for Ustekinumab?
Crohn's disease, ulcerative colitis, and plaque psoriasis comprise the major demand drivers.
4. Which markets have the highest growth potential?
Emerging markets such as China, Brazil, and India present growth opportunities due to increasing healthcare access and regulatory approval.
5. What are the key regulatory factors impacting price projections?
Policy reforms aimed at cost containment, approval timelines for biosimilars, and patent litigations significantly influence future pricing dynamics.
References
[1] IQVIA. (2022). Global biologics market report.
[2] FDA Drug Database. (2023). Ustekinumab (Stelara) approval history.
[3] Grand View Research. (2023). Biologics market forecast.
[4] European Medicines Agency. (2023). Biosimilar approvals.
[5] Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement policies for biologics.
